EPZM - Earnings call transcript Q1 2022

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Hello, and welcome to Epizyme's First Quarter 2022 Financial Results Conference Call. At this time, all participants on a listen-only mode.

Following the prepared remarks, there will be a question-and-answer session. Please be advised that this call is being recorded. I would now like to turn the call over to Kristen Hilton [ph] Investor Relations.

begin. may You

Unidentified Company Representative

the This a operator. XXXX issued press found a results. website the Thank epizyme.com. at update morning, in providing in be can business press quarter section addition release of The company's you, release Epizyme Investors to financial first

recently the are President and Officer; our President for will Jerald Joe Senior Vice Grant On Head Officer, and Agarwal, of Shefali Korn, Development Dr. call Medical Chief Adviser Medical and today and join Finance. Q&A Senior the and Bogle, Operating CEO; appointed Interim Chief Beaulieu, us session.

reminder, will SEC representing time, XX-Q, uncertainties. factors, XX-K any over filings. Factors and described in to subject Bogle. today's represent to As Forms like be call Grant statements no due results statements this undertake section a are these plans including not those of and relied publicly turn the risks views materially discussion important Actual related to views would current to to this various Risk Epizyme's recent certain which and Grant? of the obligation update our may forward-looking statements. most expectations, our our as and other These date. We differ forward-looking include At upon I as as should call subsequent of to

Grant Bogle

call, quarter. cover our for our and will and today's Kristin, SETDX and for and investigational On an provide to commercial update to today will be to the XXXX EZMXXXX, inhibitor, on you results. you, Thank first will speak our with clinical overview good performance Tazemetostat morning, great provide everyone. here our development quarter progress Shefali and It's at TAZVERIK, I Joe financials our

we'll questions. the open Following for remarks, our line

assistance trials. approximately increase Figures of when million, were quarter of a TAZVERIK represented Commercial in quarter the QX clinical commercial representing $X.X product demand QX program company TAZVERIK commercial with to XXXX. versus of generated total product fourth to sale the million, XXXX net of QX $X.X including of were XXXX, our During use the compared of XX% a in for first $X.X TAZVERIK first approximately pharmaceutical sales million XXXX. the increased related third-party quarter, revenue quarter an in first XX% XXXX XX% of XXXX. consistent rate the of patient [ph] from demand for net

demand fluctuations dynamics We in XXXX While saw demand total and fluctuations goods provided commercial benefit demand, consistent and end prescription program year-end our XXXX directionally D These in drug is and similar as Part patient quarter XXXX. at of through plus believe which, we result with part to total into impact that the QX the design demand. patterns the these are are commercial reminder, a was of prescription fourth assistance a free levels. Medicare demand

prior demand since and year, As March highest TAZVERIK rebounded in launch. in reached its the monthly level

will to seasonality demand understand needed demand of the in I'm this TAZVERIK time more relapsed/refractory FL growth. While be and on market by particular, encouraged the impact

mutation-positive ATU our prescription optimistic feedback subsequent from market our prescribing in refractory and both messaging research with grow relapse FL TAZVERIK focus, to populations, market commercial study and third-line continues company’s suggests the wild-type that for the EZHX information. share consistent the treatment and We changes FL growth continue treatment landscape upon for to based Wave and Recent survey be physician about TAZVERIK [ph] guidelines. recent to in updates

type type physician behavior plus reported our in in updated for now now relapsed/refractory infirm lymphomas. patients in physicians FL in our in EZHX the reach tazemetostat grade on suggested recently third-line for consistent reinforces sampled TAZVERIK the line guidelines label. marketplace, only disease in the wild FL prescribing B-cell Following treatment approved TAZVERIK's regimen a as treatment with remains recent therapy based and an for of mutations potential studies, [ph] confidence on The option. patients. treatment intent patients reported line with to third elderly or X-X unknown update guidelines and tazemetostat updated wild we the relapsed/refractory in NCCN changes inclusion follicular with satisfactory treatment alternative a prescribing systemic plus The third or is exciting of setting. patients. increase alternative Tazemetostat lymphoma our line include its in second both in TAZVERIK EZHX the from the FL second-line And suggested is oral more the tracking many FL that to the no setting setting

the its decision closely approved looking [ph] treatment also inhibitors of guidelines update, TG time withdrawal the Zydelig’s also December, and risk indications. Copiktra relapsed/refractory benefit SecuraBio in recent is FL was withdrawing from decision indication its Gilead's FDA by profile in inhibitors In months. followed year real of in Therapeutics all approved was to with The NCCN changing we're at a January most in in of April FL withdraw voluntary announced indication. FL the Zydelig this the improved This to landscape addition to stop Ukoniq PIXK it from witnessing In PIXK the of marketplace selling FL. in

the toxicity and to the in of data patients benefit will in [indiscernible] As support seen the on which ODAC recent hematologic the of limited this the the with risk FDA therapies ask class of advisers in specifically class absorbed evaluation to with meeting discuss whether topic are PIX malignancies.

has approximately market research of shown share. the for class market one consistently the accounts internal Our FL third that PIXK

we presents now is like growth guidelines For for turn to corresponding future this oral AZVERIK sales. commercial over opportunity believe physicians prescription the Shefali. now to to I'd call time, setting. third significant other the PIXKs approved seeking and the only therapy At in an a NCCN Shefali? plus line this with alternative update, Combined

Shefali Agarwal

good you, update our morning, and Thank begin Grant, everyone. clinical with tazemetostat. I'll

with XX, compared R-square including March lenalidomide rituximab assessing refractory the shared treated are in least systemic relapsed/refractory and/or Phase placebo with lymphoma therapy, progression experienced who years plus a of have tazemetostat X X with last the rituximab treatment. follicular disease within previously we patients of patient dosed As one study, of III confirmatory those portion our combination their with receiving first at in SYMPHONY on plus study in

are proud the and of the in to III are screening and globally, we enrolling study portion both We actively Europe Phase that patients U.S. randomized open is and share the

updated are present Clinical happy of from and overall Ib data the data the and FL specifically new effective which, more in the in to and of analysis poster PODXX and share portion subgroup We the to refractory a a updated the in The relapsed/refractory has from XX% treatments include the Annual in study, June. world rituximab study American the for safety and at XX% activity of Phase as will SYMPHONY-X Chicago patients, Meeting presentation poster accepted Society response of been upcoming complete real population know, to needed. about rate which are you Oncology

SYMPHONY-X in Phase As a portion at from data of XXXX. and were reminder, presented ASH the Ib recent December safety activity

XX safety We additional run-in year. of follow cohort this updated portion report continue later to the the patients this Phase of and study Ib data from

have plans second-line relapsed/refractory a history study evaluating begin We to natural FL CAVALLI, finalized patients. R-square in

second-line lack and outcomes of includes in the patients. rituximab relapsed/refractory PODXX the which Given population, real-world evaluating refractory data R-square the

outcomes a activity the data outcomes patient of Our to Phase may [ph] study a mimic create understand synthetic to arm study the a natural Ib better prospective control a population, goal us to randomized history to SYMPHONY-X is The design compare study. the in population. this R-square designed patient with to MASH is usage which in to R-square allow

from Our goal this in is publication to data XXXX. peer-reviewed for a submit study journal in

fully LYSA Progress the complete is has enrolled enrollment. the made Turning complete being DLBCL LYSA and is arm. near the towards to FL arm study. in

large a top high-risk frontline line anticipate is of and high-risk XXXX. portion collaboration study II results II frontline patients this in tazemetostat Phase with reminder, the DLBCL R-CHOP evaluating from and the presenting a of half in the As in study second LYSA, FL XXX Epizyme patients. Phase XX

Phase open an the portion solid PSS in well study X of of second enrolled enzalutamide tazemetostat to the a castration-resistant tumor study randomized monotherapy prostate The to continues the XX half Phase nicely. patients complete toward Ib/II in the patients. in evaluating updated Moving XXXX. of of PSXX approximately to and radiological portion to study including from compared study, plus our enrollment run-in progress interim target the metastatic is safety In the label Phase randomized XX% program, the portion in XXXX, enzulitamide as we cancer [ph] portion from present and randomized expect as data data II CELLO-X,

human the EZMXXXX. Phase relapsed/refractory well in We X/Xb to class study, EZH-XXXX, in myeloma of continue screen which oral patients ARIA, multiple relapsed/refractory known Phase otherwise inhibitor as basket study Xb/X hematological first DLBCL. first patients is SETDX adult with and as in novel Epizyme SET-XXX, in tazemetostat as

for antibody lines with tezmeostat Ib/II prior CDXX For engaging ARIA, investigational received of hematological bispecific the cell who combine or with of study two visit have CDX Phase therapy. the Roche's relapsed/refractory follic T mosunetuzumab, will patients more

the the escalation SET-XXX, XXXX. programs enroll in both company to For provide these study. in the Phase patients expects I XX XX half dose on the portion of plan between updates to We of of second to

years. a second the to in tazemetostat our the for year of development cadence see, advance coming As can and we EZMXXXX through program continue steady you and this anticipate and half data of

plan Our track. expand post-marketing ongoing the on also the SYMPHONY-X label. leverage to post-marketing We trial are commitments to and commitments TAZVERIK the fully FDA confirmatory

of tazemetostat malignancies. evaluations intended label. have to of pharmacology clinical heme or post-marketing We effect inform the the effect inducers solid studies on underway for CYPXA tazemetostat inhibitors function on and patients of aspects and the liver include several These assess to with

at a Phase paired II to tumor to biopsy of total adults expanded patients. is with immune have least assess enroll cohort potential of a cohort in enrollment The a XX ES We biomarkers. INIX-negative our in also study design

pass Finance. treatment share Head that would as previously. a FL, terms update more referenced of appropriate time, I'd and didn't as current which of relapsed/refractory FL. which Senior the to I in be to making this mutation are Joe, status to regardless the remiss changes, NCCN informed decisions they closely recent the Vice aligned consider like I our At with physicians guidelines if the label relapsed/refractory excitement Finally, and call of in President These clinician Grant for my support patients options

Joe Beaulieu

We Shefali. with equivalents million you, ended securities. first cash $XXX quarter marketable approximately in Thank and cash, the

runway first to million were of first We guide our quarter the XXXX. into $XX quarter non-GAAP were million operating adjusted cash operating for the XXXX. approximately continue for expenses expenses third quarter Total $XX approximately of XXXX. the Total of GAAP

recall, XXXX operational measures last As efficiencies. may year expense on quarter, operating revised our based we expense you guidance reduction and full

million We non-GAAP would to remarks. for now $XXX I closing of the turn expect Grant? operating $XXX million. expenses to back total adjusted call Grant to continue between XXXX to like

Grant Bogle

thank session, obviously joined be Officer. Korn, I also by very to Joe In questions. you, we'll Thank Shefali, was a Q&A Jerald This good forward you, new Joe, and look update but and and Chief Shefali. our the Operating

we as be and the MC the line appropriate of okay. questions kind person, open as serve first I'll them, to to one I'll So to

So the why don't we open now. line right

Operator

Thank question Lawson [Operator line Peter Barclays. Instructions] from first Our comes you, sir. the of from

Peter Lawson

the be much. question taking that around confidence around that rebound so - questions. would you essentially first the Thanks Thank Great. I Thank details you in for is have be revenues QX, for guess a any the would you. great?

Grant Bogle

that one what information. been continued I quarter into And April, on We more years. Peter, in, in what that's is what from I And tell to It's scope they safety we're physicians think the probably where that But in I'm put setting. this have a profile, future strong been predict, research the in in is what many, only that very the that being unknown as we the tolerability TAZVERIK, and done. changes, market where quite which they're and therapies physicians of market haven't rebound the we frankly, but has this wild is the But obviously our - reported just type patients, especially many of the is just but many see in well. oral We're shown of most PIXK is of that. there's hear the in think, are not patients are I the And last population. on the because that not not and That the month projecting efficacy, our holds, Feb in oral now the is because can is for of that's profile, I did excited is in agent approved third-line this from of growth opportunity the the is significant is that change think terms you something difficult broader than a used mutant in because processing population. setting, most. the plus the quarter, March. actually other of for because we

all and NCCN the starts with a reasons, patients sense, build XXXX those when component kick-in. guidelines, to would the lines And you've because that and this is I'm Does into I half so therapy say of got it for if would quite encouraged. back of more Peter? make that then

Peter Lawson

was question. That Yes. my follow-up actually

more of get think you that... the to backup you're of PIXKs, - off the So waiting come patients where that's a you because for that's

Grant Bogle

Yeah. guidelines in colleagues physicians I'd you these so if Remember, market. US with the I if and updated, the at are things, like not pulled most you system. available. to you well, get [ph] Oncology, know, But it through Shefali? those but is there of in still patient drugs things types get - ask clinician remain exception like if probably working tell changes a each my NCCN pulls you take And weighing change, various doing - of from generally all it's years pathways all that immediate think your got chronic, the is an the I the as can with experience drugs for through, many especially is available of

Shefali Agarwal

absolutely right, Grant. Yeah,

- I well. do follicular lymphoma you patients indolent tumor, think and as is actually know, an the

And to patient if that you And line it therapy that therapy, is the tend well. the now in to but in FL, aligned generating, see, or oral believe availability other PIXK not all with second a label, TAZVERIK really in also they're as be made, and for We talk hem well, label. know, physicians update, TAZVERIK for example, in the continuing, our approved therapy about NCCN will and additional are but that doing that that third as TAZVERIK. will there's that we data great with of point was now additionally, the potential substantially combination terms value Grant if trials is although and in line beyond. of potential Peter, the only we we'll - of the we the on symptomatic, other to important great change So we as be add solid malignancy only any not think I not tumors, and

Peter Lawson

of beginning a effect Okay, question fine. any Omicron just Thank months the And seen at any weakness have way breaking the Is you there that in on of year. final you. out of first the few may year? COVID, the

Grant Bogle

the year. experience this Medicare would that. last the other we short lockdowns answer the I as country are that as do as year is get well of lot a really or forth. the drug There is, in and tumor, drive they of re-upping know, the two all so classes, I that to things were forth. the what which, they you different semi or to as you - aspect One the out so prescriptions say of drug all donut-hole of that to to relates saw end year, us patients, portions of Peter, can't impacts the decide and refills and the I honest be enrolling quantify things these the is and given that think the with and Like that affect things, benefit, how company factors. my dispensed of were towards the the second But end design you really And

orals. can't That's So all other I've think tease what are read everything, and - predominantly. if in similarly COVID classes, growth. the I since it it we've of there was can't those year, was seen seen out last not it - I effect a I but out

Peter Lawson

Got you.

much. you Thank Okay. so

Grant Bogle

Thanks, Peter.

Operator

from ahead. you. of our question the Cowen. show Peyton I line go from Please next Bohnsack Thank comes

Peyton Bohnsack

I I any follow-up. any are our details you additional pre-prescribers the of first elaborate since all for how evolved to integrating the how over TAZVERIK And guess information good number base and moderate hospitals for prescriber time? changed that's launch? have on new also, prescribers on what and that's just give? versus can one, then a the on for TAZVERIK provide This [ph] you. Thanks Joe. guys. be number And you morning, Thank or Hey, the questions. Specifically, of additional could is taking Payton

Grant Bogle

Okay.

was and maybe So the talk the begin we But to plus you see volume on with, is was time. and up was that sarcoma, XX% the when you the you given epithelioid TAZVERIK the fact that’s is in goes up of not And about down greater concentration and bit that, at over were it is with And is environment. in was know, a community I a in have that in was can me than all here, ES broadly setting board. the Shefali the on the uptake more community. it start, the environment just in you in patients split that since treat community the the XX% how it community community and do our academic a the population, than patient and academic the introduced, today, distributed between in academic little United let environment, what migration probably greater setting. to which comment but States the lymphoma launched, [indiscernible] balance predominantly follicular taken roughly the And in in in academic it There's in predominantly roughly environment. physicians of academic they

in So some environment. that dynamics you different get on

pharmacy are Dr. is you specialty distributor have growth know, prescribers, something distributor the that's In and drug ES a that's terms whether when or of so drug new got that's Oncology. tell patient from assessing pharmacy, we difficult it's on. understand We a of we a of a it's Smith either only prescriptions time through we've one, Kettering that. volume XX% channel. But patient is can at goes specialty through that refill, to are Minnesota our because, doctors which to or a if FL, they that which Memorial a of really our - XX% dispensed from it's as from [ph] track This forth. the sent is can't we Sloan the set When

don't Many have a ordered see with What to growth visibility coming times, are we already continuing accounts accounts on in I account the past. in board. is is tell you are So that. parent that satellite of we will more these

lot some around those issues have. be recently, ordered into the access I we because some this never they sure for of have of coincident with and was did direct accounts don't have we can't and see a timing the But However, challenges accounts. the PIXKs that

speculate, as be to sign. related I positive it might could one but but that, So view that a

So physicians the I of of to changes, in the really our our rethinking population how focusing are TAZVERIK, expanding in NCCN light setting. commercial think simplifying and the guideline position strategy in broad especially wild-type on the change message use and terms

think I So impact. an are Did answer those that your question? having changes

Peyton Bohnsack

trial to Thank helpful. really Yeah. recent issued the all the I the Hutchmed, that. of due then and secondly, FDA [ph] rejecting data studies clinical for That Thank you. guess in Does on Phase with in the CRL was Thanks combination enrollment you. read-through And generated effort? due III to routine study to this to portion tazemetostat China have planned any or studies. the SYMPHONY kind any color U.S.

Shefali Agarwal

just is simply as know, discussion of working goal in China, I you enroll open and the don't big that's think I still we of many have there's sites. sites patients sharing study - but I as China, as overall. with as we thing question Overall, currently, and a focus not to terms although to are Europe. XXX to our there's a one we that really really And PIXK a about sites Our think I know, We possible partner, globally, U.S. quickly in really, our specifically right? PIXKs for in that design, you about is that think - think is XX% China, but XX%. the other completion, to have globally. get it

as are We screening going well. patients to be globally enrolling

can So don't I because your trial. about we see I impact enroll that SYMPHONY-X an of kind to be on although CRL, this - I many do question understand see do sites able have but

Peyton Bohnsack

very perfect. right, All Thank you much.

Grant Bogle

Thank you.

Operator

line of next our from Please from comes Michael question Jefferies. show the Yee go I ahead.

Grant Bogle

Mike. Hey,

Unidentified Analyst

on Yee. Congrats Michael have for a question getting this the first into guidelines QX on NCCN and I inhibitor. time on My Sid just revolves few on is SETDX This revenue. a questions lot.

as expect good we're ASH? And do You said see to can you we we see? Could to result? any expecting to can us give expect you what second more guidelines a at as what data data that And expect kind sometime half. of

Shefali Agarwal

Yeah.

very So SETDX as EZM-XXXX you excited know, are inhibitor, SETDX is the that. first the clinical and about we

Phase is an we get escalation trial, to terms And goal As efficacious in escalate such, into MTD. levels. dose dose six really of I in the for and it's are trial, or human doing first a maximum dose the

We are patients. screening

data, that just that's SETDX data, multiple have the we need. myeloma. sites terms for escalation, as - because not we label, the at any important certain time, are open. in be time of specifically I Eventually, And it's open thing And but We inhibitor a can. important TXXX big unmet at dose it's think is very the translocation we'll presenting is

first-in-human. non-TXXX additional dose about So and cohorts And TXXX that patient doing and patients, But add and in non-TXX are have enrich then our first-in-human for eventually of the specifically we are result, XX design have once not That's that expand would DLBCL. we patients on but that only we dose DLBCL. goal also our for trial. a that is as that to a

And is I would as know that what need. TXXX of of an there's well terms poor. particular really the a opportunity would that, because say, prognosis think we like subset win, in we've the don't is big unmet a work there's heard, patients In I therapies myeloma considered and multiple in

study to opportunity in an there's that part. registration monotherapy and possibly population So a

activity, forward. first-in-human be be open-label presenting we as know, data, But as provide guidance on that when data And that we to data goal to able we'll you possible will quickly as path second have we well. progress, we we'll to as our - we biomarker data. with present agency year. possibly trial half as But about enroll is the this to Now get are safety, of eventually, do the more discuss that get

Unidentified Analyst

Is question commercial taz. seen quarter-on-quarter commercial to on trying had modest a are increases just quarter-on-quarter second revenue? Thank you What focus screening with that. generate the it access your Is forward? We've for And market you in to of - of status of revolves kind physicians? kind dependent just EZHX moving strategy. kind it strategy? What's I strategy overall on growth year for

Grant Bogle

of great question, and I the of you in how that. pretty the in of the are It's do the terms So do some meeting payer access their straightforward. to we not physicians and in up. in our majority and up, can asked terms frankly, is oncology I'm I we're straightforward. patient and don't terms to on challenges and say they of of evolved quite message. We on to vast getting terms access simplifying prefer that. it from and offices really it's down a access, they they're opening glad focusing But they're electronically, has fact standpoint. be - broad population. own lock but continue busy like just with they would in we're that other cases, have opening issues, There environment, But strategy, We're We're caregivers providers and the if engaging in mean, pretty really kind a COVID of nature that

launch a not was intuitive potential. of marketplace, the in the And changes the as then the most to interactions. exactly care from education, on know leveraging appropriately standpoint from NCCN understanding are which into through as the well sets, through educate the guidelines continue into to the systems the it's you driving putting that really pathways, as of physician in terms label, it it through over We driving full

sauce education. I just about here. wish some could is - So there secret I was This

depth resounding of in board me data, appreciating couple feedback are drug not the from tolerate the how amount the was colleagues we the even this at had fact that really in with can weekends behind many of Shefali, - time, wild think Physicians just get this, the an patients on we type, data, physicians performs, mutant advisory other with have one, fair the just just the ago, that we data here. in out I the [ph] point last population. just of physicians here a TAZVERIK

So factors taken the a that's really should faster, have time. been of there's lot Shefali? We have but focus. that

Shefali Agarwal

Yeah, I understanding initially the COVID physician. that things as think TAZVERIK, of was course, about and challenge the of just there's you then, thing reaching think label one an important a to of the is

Grant in same. not mentioned, of the about saw well. There's when the data. difference durability is The due both. importance It's as to response discussed And works may that's is and agency we physicians as is demographics - challenge. Now that, educating the talked just the it wild-type with the however, the of It that same. the PFS be a absolute in rate, population patient we as

So the goal is data. to that really educate physicians understand about that data,

bring that we is also overall combination. [ph] But important is as can as And big our is. focus the population. used what data thing be in could it broad So and

So combination. started are we towards with we moving but monotherapy,

create in that, patient a we the We have tumor SYMPHONY-X is are synthetic that to data. solid data have we CELLO-X lead do real-world actually going to this great then as mentioned XX will with control, study that I a script,

We have well. LYSA as data other patients combination in frontline and high-risk

clinically cost of cadence we data to medically understand So and only that and TAZVERIK, talk think realize monotherapy I combination, data, of we that can we that, as about would goal. value cannot although our and promote the not but but be as also

Grant Bogle

light about group skill simplifying mentioned is appropriate to based to size have worked on to educate systems an been all change And new a additional of we our think we sets We've as that that, we we how group. this a like There's One Shefali a know, leadership. of commercial way is on briefly on need this sorry there's this, of message. a affairs talk The long also the the in just real lot little that opportunity increased And answer. the data. Jerald I'd bit ask restructured the We've in changing on made, we just medical Jerald? changes. data you I'll Jerald touch brought and I'm organization, of that comment care. understand in new too, that

Jerald Korn

Yes, is Grant. Thanks, education critical. we think this

quantity setting. morning, And physicians. As keeping that the many we the this you can community community lot in year. of occurring ocular of challenging talked with see treatment small while only out broadly come disease occurred individual But when that overall oncologists development up per some development with patients about oncology and be nature annually, of that setting, community a a number in the for treatment combine indolent the the is lymphoma the of

it's marketplace to reach to changes those can identify TAZVERIK So we as educate data. well incumbent appropriately and the us they're physicians, our updates guidelines, and NCCN all on aware of on the in the as so ensure

resources that's put lot team affairs our and out we've go identify at across community and into a sure the we medical those can country. physicians this really focus this And time. making So that more the of

Grant Bogle

Thank you, Jerald.

Unidentified Analyst

for Thanks that.

III from in Hutchmed much And lockdowns, As the are can have slowing in of payments somebody you. enrollment quick one lastly, you works expect challenges. do portion that any developments It will clinical time, understand down I you seems that be question. Phase for China. to seeing Due any SYMPHONY-X, market those of for access, last III the in If Phase we portion? the Thank milestone of enrollment? just

Shefali Agarwal

Yes.

me from clarify. China. the Actually, just expecting don't patient our we contrary, Let its on have

in handful them XX Europe China. U.S. Majority would have in and US, sites them in actually and of sites about are a only to globally are XX be We very of XXX

China. the really study was It's not goal in the globally. across So to enroll specifically

there know, you about patients. are As XXX

So we as and US ex-US China would sites well to sites, all enroll. use

we sure that. in China, with partner, just those to dependent challenges But can we is in are Hutchmed that start lockdown working we terms make not there activities in on overall, right, and are China. absolutely You're our of

these continue all have We we'll across world. sites the that enrolling

Grant Bogle

our know, milestone you And for to yes, milestone but believe as related the amounts, I also global and simply randomized payments, expense milestone important disclosed It's us. there's the some are large trial. they are there payments, we and some offsets, what but payments, don't a clinical SYMPHONY-Xs

for of the pick expense patients of as portion And both that fair agreement, So China. agreed enrolled that to are amount a in Hutchmed there. up our has of there's part

not not Shefali although amount, - majority of So as and an patients said. the that's that's insignificant

Shefali Agarwal

add to now just in ex-US, I US, enrolling. many and III in Phase And sites is SYMPHONY-X we want open globally screening that is, are It's the to open. patients

quickly to trial very We as enrolled get hard are as this really possible. working

Unidentified Analyst

you I time. it. Thank for appreciate Wonderful. your

Grant Bogle

Thank you.

Operator

questions to Thank Mr. Instructions] I'm for this further no [Operator remarks. call showing Bogle, the you. at Grant closing back queue in CEO, I'd like the turn to time.

Grant Bogle

to point shortly. and you joining of is that well debt, you, revised to available and now encourage our as very I today. follow-up This posted be we us would thank calls to for also website, helpful. have this everybody corporate Thank is the on out download will which want I as recorded updated needed. Ben. I meeting course, it. And like for We're And

I with hope So great everybody that, I day. you, thank the and has rest of a

Operator

This concludes for you today's conference participating. call. Thank

disconnect. now may You

Epizyme (EPZM) 10 May 222022 Q1 Earnings call transcript